SCHEMBL4220082

SCHEMBL4220082

Cn1ncc2c(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)cncc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.64
KIT P10721 8/20 0.54
FLT3 P36888 7/20 0.54
CSF1R P07333 6/20 0.54
LYN P07948 6/20 0.54
FLT1 P17948 6/20 0.54
FLT4 P35916 6/20 0.54
BLK P51451 6/20 0.54
AURKB Q96GD4 6/20 0.54
ROCK2 O75116 5/20 0.54
MAP4K4 O95819 5/20 0.54
RET P07949 5/20 0.54
FGFR1 P11362 5/20 0.54
RPS6KB1 P23443 5/20 0.54
EPHA2 P29317 5/20 0.54
FRK P42685 5/20 0.54
CLK2 P49760 5/20 0.54
RPS6KA3 P51812 5/20 0.54
MAP4K2 Q12851 5/20 0.54
ROCK1 Q13464 5/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4232674 0.88 KDR (0.82) KDRKITFLT3CSF1RLYN
SCHEMBL3846464 0.88 KDR (0.64) KDRKITFLT3CSF1RLYN
SCHEMBL3844631 0.88 KDR (0.62) KDRKITFLT3CSF1RLYN
SCHEMBL4218145 0.87 KDR (0.69) KDRKITFLT3CSF1RLYN
SCHEMBL3847114 0.85 KDR (0.62) KDRKITFLT3CSF1RLYN
SCHEMBL4221396 0.85 KDR (0.62) KDRKITFLT3CSF1RLYN
SCHEMBL3842232 0.85 KIT (0.70) KDRKITFLT3CSF1RLYN
SCHEMBL12322989 0.84 KDR (0.60) KDRKITFLT3CSF1RLYN
SCHEMBL3846432 0.83 KDR (0.59) KDRKITFLT3CSF1RLYN
SCHEMBL14176479 0.82 KDR (0.58) KDRKITFLT3CSF1RLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125808-A2 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME Bayer Schering Pharma Aktiengesellschaft (DE) 2009-12-02 EP claimed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US claimed
WO-2008071456-A2 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-19 WO claimed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US disclosed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US disclosed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US disclosed
WO-2008071456-A2 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. KDR, FLT4, TIE1 KDR 1/4885KIT 93/4885FLT3 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.